Literature DB >> 678451

Corticosteroid effect on epidermal cell size.

C Delforno, P J Holt, R Marks.   

Abstract

Changes in the epidermis following application of three corticosteroids, betamethasone 17-valerate, hydrocortisone 17-butyrate, and hydrocortisone have been studied histometrically in human volunteers. The reduction in epidermal thickness observed correlated significantly with a reduction in size of the viable epidermal cells. There was no significant reduction in the number of cells constituting the viable epidermis. These findings indicate that thinning of the epidermis is a function of cell size rather than cell number. The epidermal changes developed quickly and were rapidly reversible. It is suggested that measurement of cell size may be an early and sensitive index of atrophogenicity induced by topical corticosteroids. 0.1% Hydrocortisone 17-butyrate and 0.1% betamethasone 17-valerate showed equivalent potency in causing epidermal thinning and reduction in cell size. Reduction in cell size paralleled increasing concentrations of betamethasone 17-valerate, indicating a positive dose-effect relationship.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678451     DOI: 10.1111/j.1365-2133.1978.tb03579.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review.

Authors:  K L Goa
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Is half strength of 0.05 % betamethasone valerate cream still effective in the treatment of phimosis in young children?

Authors:  Paiboon Sookpotarom; Chanchuree Asawutmangkul; Benjaporn Srinithiwat; Sucheera Leethochawalit; Paisarn Vejchapipat
Journal:  Pediatr Surg Int       Date:  2013-04       Impact factor: 1.827

3.  Corticosteroids induce proliferation but do not influence TNF- or IL-1 beta-induced ICAM-1 expression of human dermal microvascular endothelial cells in vitro.

Authors:  U Hettmannsperger; S Tenorio; C E Orfanos; M Detmar
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

4.  Longitudinal in vivo tracking of adverse effects following topical steroid treatment.

Authors:  Andrew J Bower; Zane Arp; Youbo Zhao; Joanne Li; Eric J Chaney; Marina Marjanovic; Angela Hughes-Earle; Stephen A Boppart
Journal:  Exp Dermatol       Date:  2016-02-13       Impact factor: 3.960

5.  Topical corticosteroids: clinical pharmacology and therapeutic use.

Authors:  J A Miller; D D Munro
Journal:  Drugs       Date:  1980-02       Impact factor: 9.546

6.  Epidermal thinning: evaluation of commercial corticosteroids.

Authors:  R Wrench
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

7.  Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy.

Authors:  Hanne Norsgaard; Sandrine Kurdykowski; Pascal Descargues; Tatiana Gonzalez; Troels Marstrand; Georg Dünstl; Mads Røpke
Journal:  Arch Dermatol Res       Date:  2014-07-16       Impact factor: 3.017

8.  Pilot parallel randomised controlled trial of protective socks against usual care to reduce skin tears in high risk people: 'STOPCUTS'.

Authors:  Roy J Powell; Christopher J Hayward; Caroline L Snelgrove; Kathleen Polverino; Linda Park; Rohan Chauhan; Philip H Evans; Rachel Byford; Carolyn Charman; Christopher J W Foy; Colin Pritchard; Andrew Kingsley
Journal:  Pilot Feasibility Stud       Date:  2017-10-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.